Deciphering human heart failure with preserved ejection fraction (HFpEF) at single cell resolution

  1. Lukas Zanders
  2. Simone F Glaser
  3. Mariano Ruz Jurado
  4. Moritz Brandt
  5. David John
  6. Luka Nicin
  7. David Rodriguez Morales
  8. Wesley T Abplanalp
  9. Tara Procida-Kowalski
  10. Franziska Ganß
  11. Evelyn Ullrich
  12. Alisa Debes
  13. Penelope Pennoyer
  14. Marek Bartkuhn
  15. Reinhard B Dettmeyer
  16. Andreas M Zeiher
  17. Eike Nagel
  18. Philip Wenzel
  19. Stefanie Dimmeler
Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

BACKGROUND

Heart failure with preserved ejection fraction (HFpEF) is a complex and growing condition, representing over half of all heart failure cases. Despite its high morbidity and mortality, its heterogeneity and limited therapeutic options pose significant challenges. Understanding the molecular mechanisms driving HFpEF is essential for the development of new therapies to improve patient outcomes.

METHODS

We performed single-nucleus RNA sequencing of nuclei obtained from endomyocardial biopsies of six patients with HFpEF. The obtained dataset was integrated with a dataset of 12 healthy human hearts and their transcriptomic differences were analyzed.

RESULTS

After quality control and integration of the datasets, nine major cardiac cell types were annotated. HFpEF cardiomyocytes were characterized by a reduction in genes associated with aerobic respiration and fatty acid metabolism and showed an upregulation of RHOA/ROCK1 signaling, which was validated using immunofluorescence staining in human HFpEF myocardial sections. Endothelial cells exhibited signs of increased apoptosis, SEMA3 signaling and signs of reduced VEGFA signaling as well as a reactivation of a fetal gene signature. In line with a prominent role of cardiac fibrosis in HFpEF, we observed increased signs of fibroblast activation and proliferation, and reduced signs of IFNɣ signaling in HFpEF which was most pronounced in activated fibroblasts. Treatment of human cardiac fibroblast with rhIFNɣ resulted in decreased collagen contents. Macrophages from HFpEF myocardium showed a pro-inflammatory transcriptomic signature and showed increased expression of MHC-II molecules. This was associated with signs of an increased IFNɣ response.

CONCLUSION

Our results provide insights into the transcriptional diversity of HFpEF recapitulating structural, functional, and molecular hallmarks of the disease and provide mechanistic insights which might represent therapeutic targets and biomarkers to improve outcome of patients with HFpEF.

CLINICAL PERSPECTIVE

What is new?

  • We provide a single-nucleus RNA sequencing (snRNA-Seq) dataset from human HFpEF myocardium and demonstrate feasibility of snRNA-Seq from endomyocardial biopsies

  • The snRNA-Seq data confirms signs of known molecular hallmarks of HFpEF, such as metabolic changes, inflammation and fibrosis

  • We identify signs of regulating cellular mechanisms underlying these hallmarks, such as cytoskeleton remodeling via RhoA/ROCK1 in cardiomyocytes, and differential interferon gamma signaling in stromal and immune cells

What are the clinical implications?

  • We provide several cell type-specific cellular mechanisms which might serve as biomarkers or therapeutic targets in the treatment of HFpEF

Article activity feed

  1. Version published to 10.1101/2025.04.02.646923 on bioRxiv